Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mixed amphetamine salts (Takeda)
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Mixed amphetamine salts is a central nervous system (CNS) stimulant medication primarily used for the treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy. It consists of a specific 3:1 ratio of dextroamphetamine and levoamphetamine salts, specifically dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate. The drug works by increasing the synaptic concentrations of the catecholamines dopamine and norepinephrine. This is achieved through several mechanisms: the inhibition of reuptake transporters (DAT and NET), the promotion of neurotransmitter release from presynaptic neurons via interaction with the trace amine-associated receptor 1 (TAAR1), and the modulation of the vesicular monoamine transporter 2 (VMAT2). Originally developed by Richwood Pharmaceuticals (later acquired by Shire, now Takeda), it is available in both immediate-release and extended-release formulations.
- Brand names
- AdderallAdderall XRMydayisAdzenys XR-ODTDyanavel XR
- Other names
- MASamphetamine salt combodextroamphetamine saccharate + amphetamine aspartate + dextroamphetamine sulfate + amphetamine sulfate
02
Targets
DAT (Dopamine plasma membrane transport protein)TAAR1 (Trace amine-associated receptor 1)SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)VMAT2 (Vesicular monoamine transporter 2)MAOA (Monoamine oxidase A)
Beyond the preview
Go deeper on mixed amphetamine salts (Takeda).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mixed amphetamine salts (Takeda).